ClinicalTrials.gg

Program

revumenib

Also written as “Revumenib”.

Its studies are mostly in Leukemia, Myeloid, Acute · Hematologic Neoplasms · Colorectal Neoplasms · Leukemia, led by Syndax Pharmaceuticals.

Furthest: phase 3, since Sep 30, 20256 company-led studies, 4 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Syndax Pharmaceuticals64 open or runningphase 3since Sep 30, 2025Aug 16, 2019Feb 2027phase 1 · NCT06226571

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 16, 2019First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT04065399 · 447 planned · United States, Australia, Canada and more
  2. Jun 1, 2022Phase 1 study in LeukemiaNCT05406817 · 9 enrolled · United States
  3. Feb 7, 2023Phase 2 study in Colorectal NeoplasmsNCT05731947 · 41 enrolled · United States
  4. Jan 12, 2024Phase 1 study in Leukemia, Myeloid, AcuteNCT06226571 · 96 enrolled · United States, Australia, Canada and more
  5. Sep 30, 2025Phase 3 study in Leukemia, Myeloid, AcuteNCT07211958 · 468 planned · United States, Argentina, Australia and more
  6. Oct 28, 2026Phase 1 study in RecurrenceNCT07923071 · 18 planned

Ahead

  1. Feb 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06226571
  2. Dec 15, 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT04065399
  3. Jun 2029Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT07211958
  4. Jan 2030Primary completion: phase 1 study in RecurrenceNCT07923071

TargetBeta

KMT2A →MEN1 →read by rule
“An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, ”NCIt, by rule
“Menin/Histone-lysine N-methyltransferase MLL inhibitor; Menin inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
bleximenibJohnson & Johnsonphase 34

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07923071Recurrence1Not yet recruitingJan 203018
NCT07211958Leukemia, Myeloid, Acute · United States, Argentina, Australia and more3RecruitingJun 2029468
NCT06226571Leukemia, Myeloid, Acute · United States, Australia, Canada and more1Active, not recruitingFeb 202796
NCT05731947Colorectal Neoplasms · United States2TerminatedJun 30, 202541
NCT05406817Leukemia · United States1CompletedNov 18, 20249
NCT04065399Leukemia, Myeloid, Acute · United States, Australia, Canada and more2RecruitingDec 15, 2027447

How it is read

Names in the registry

  • “Revumenib”, 5 entries
  • “revumenib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.